# Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism

> **NCT02558270** · PHASE2 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 20 (estimated)

## Conditions studied

- Type 2 Diabetes
- Metabolically Healthy Controls

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02558270
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558270, "Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02558270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*